 Results Indicate That Endotracheal UVA Light Catheter Therapy is Associated with Significant Reduction in SARS-CoV-2 Viral Load and Improvement in Clinical Outcomes in Mechanically Ventilated COVID-19 Patients ENGLEWOOD, CO ACCESSWIRE June 28, 2021 Aytu BioPharma, Inc. NASDAQ:AYTU, a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that data from the first in-human, open label, clinical trial studying the safety and effectiveness of ultraviolet A UVA light endotracheal catheter therapy was published online on June 26, 2021 in the peer-reviewed journal Advances In Therapy. The UVA light catheter technology utilized in this study is the basis of Aytu BioPharmas HealightTM medical device which has been exclusively licensed worldwide for all endotracheal and nasopharyngeal applications. 